SEC Tracker
Get the app
TOVX · XBRL financial data

Theriva Biologics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TOVX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers——————————3000*
Research and development4,0064,196*3,4592,9532,7342,886*2,9681,9532,5511,132*3551,268
General and administrative2122,021*1,9331,4672,3021,694*1,44911,1791,889931*2,0722,027
Total operating expenses4,2186,217*5,3928,4887,8874,580*4,41713,1324,4402,063*2,4273,295
Operating income (loss)(4,218)(6,217)*(5,392)(8,488)(7,887)(4,580)*(4,417)(13,132)(4,440)(2,063)*(2,127)(3,295)
Interest income382312*228173158138*96546572*8279
Interest expense—————year only1216—year only1617
Income tax expense (benefit)(527)(424)*———year only——————
Net income (loss)(3,303)(5,485)*——————————
Earnings per share, basic‡ USD per share(4.75)(8.00)*(7.50)(10.75)(6.81)—(1.55)(1.93)(0.45)—(0.05)(0.07)
Earnings per share, diluted‡ USD per share(4.75)(8.00)*(7.50)(10.75)(6.81)—(1.55)(1.93)(0.45)—(0.05)(0.07)
Weighted average shares, basic‡ thousands of shares682683*6867761,134—2,7826,7539,677—41,07345,893
Weighted average shares, diluted‡ thousands of shares682683*6867761,134—2,7826,7539,677—41,07345,893
  • ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
  • † Share count changed about 3x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TOVX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents31,16023,17718,26116,59316,40911,60910,01412,1207,52813,05614,43111,337
Prepaid and other current assets2,2082,4141,6231,3631,2921,4448759016541,060630653
Total current assets34,76727,40321,65619,71519,53316,28112,47614,7439,90317,46716,75713,671
Property and equipment, net389422375336314270253258249222194173
Right-of-use asset1,8311,7591,6341,5191,4281,2721,1711,0779428031,9461,825
Goodwill5,4605,7005,5731,465—0——————
Total assets61,54555,21948,73042,39040,10835,35232,16135,83030,83638,23938,24834,857
Accounts payable8337705719357568594376077951,014608984
Accrued liabilities5,5902,9953,3273,4893,7543,3683,7699,0177,6856,2766,2206,418
Total current liabilities8,7436,7386,0096,8487,3237,5858,14812,39411,00310,01410,26412,111
Lease liability, non-current1,5461,4421,2991,1621,0358737325844333521,5221,374
Total liabilities17,66115,52214,60714,74415,47316,28516,66425,20724,09822,85622,84922,670
Accumulated deficit(303,834)(309,318)(314,483)(322,799)(330,525)(334,971)(339,295)(352,353)(356,714)(358,710)(360,754)(363,971)
Total liabilities and equity61,54555,21948,73042,39040,10835,35232,16135,83030,83638,23938,24834,857
Common shares outstanding (cover page)‡ thousands of shares6826866911,0052,7822,7828,1879,59833,74045,89345,89345,893
  • ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
  • † Share count changed about 3x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TOVX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(3,303)(5,485)*——————————
Stock-based compensation135*145*160172*177*162*100173*228*153*135135*
Depreciation and amortization32*39*3938*33*27*2627*28*27*2424*
Net cash from operating activities(2,953)*(6,541)*(4,881)(3,452)*(3,913)*(4,691)*(4,756)(4,712)*(4,319)*(2,882)*(2,456)(3,085)*
Purchases of property and equipment129*56*——0*0*——19*0*——
Net cash from investing activities(129)*(56)*——0*0*——(19)*0*——
Proceeds from issuing common stock————————0*———
Proceeds from long-term debt——————1,40157*34*15*——
Repayments of long-term debt0*0*——0*0*56—————
Net cash from financing activities1*(1,457)*——3,716*7*3,0726,811*(148)*8,458*3,866(14)*
Net change in cash(3,092)*(7,978)*(4,919)(1,668)*(180)*(4,807)*(1,591)2,052*(4,592)*5,528*1,374(3,095)*
  • † Share count changed about 3x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Theriva Biologics11,3370*(3,085)*45.9M3.7 quarters 10-QJun 30, 2026
Jaguar Health3,7881,225(5,338)*not reported0.7 quarters 10-QJun 30, 2026
Healthy Extracts1902,067306*14.7M— 10-QJun 30, 2026
Q/C Technologies308not reported(1,819)*8.2M6.0 quarters 10-QJun 30, 2026
Polomar Health Services1791,529121*28.4M— 10-QJun 30, 2026
Enveric Biosciences8,296not reported(2,445)*4.5M3.4 quarters 10-QJun 30, 2026
China Pharma Holdings305948(33)*43.0M9.3 quarters 10-QJun 30, 2026
Synlogic13,1830(922)*12.2M14.3 quarters 10-QJun 30, 2026
Integrated Biopharma4,471not reported(1,194)*31.1M3.7 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.